IP Library › Granted Patent US 12,202,870
Granted Patent B2
US 12,202,870 · App. 17/455,617 · Granted Jan 21, 2025

Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof

Inventors: Maria Amann (Duebendorf, CH); Peter Bruenker (Hittnau, CH); Christina Claus (Ennetbaden, CH); Claudia Ferrara Koller (Zug, CH); Sandra Grau-Richards (Birmsdorf, CH); Christian Klein (Bonstetten, CH); Viktor Levitski (Schlieren, CH); Ekkehard Moessner (Kreuzlingen, CH); Pablo Umana (Wollerau, CH)
Assignee: Hoffmann-La Roche Inc.
C07K14/525A61K39/395C07K14/705C07K14/70596C07K16/2803C07K16/2863C07K16/2887C07K16/3007C07K16/3053C07K16/40A61K38/00C07K2317/31C07K2317/526C07K2317/55C07K2317/60C07K2317/622C07K2319/035C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,202,870
App. No.
17/455,617
Granted
Jan 21, 2025
Kind
B2
Abstract

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Claims (78)

1. A TNF family ligand trimer-containing antigen binding molecule comprising

(a) at least one moiety capable of specific binding to a target cell antigen,

(b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other, optionally by peptide linkers, and

(c) a Fc domain composed of a first and a second subunit capable of stable association with each other, wherein the Fc domain is an IgG1 Fc domain or an IgG4 Fc domain, and

wherein the antigen binding molecule comprises

(i) a first heavy chain comprising the VH domain of a Fab molecule capable of specific binding to a target cell antigen,

(ii) a light chain comprising the VL domain of a Fab molecule capable of specific binding to a target cell antigen, and

(iii) a second heavy chain comprising the amino acid sequence of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO: 8, SEQ ID NO:99, SEQ ID NO: 100, SEQ ID NO: 101 SEQ ID NO:102 or SEQ ID NO: 103.

2. The TNF family ligand trimer-containing antigen binding molecule of claim 1

wherein said three ectodomains of a TNF ligand family member or fragments thereof are connected to each other by peptide linkers.

3. The TNF family ligand trimer containing antigen binding molecule of claim 2

wherein the polypeptide comprising the three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers is fused to the N-or C-terminal amino acid of one of the two subunits of the Fc domain, optionally through a peptide linker.

4. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the TNF ligand family member costimulates human T-cell activation.

5. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the TNF ligand family member is 4-1BBL or OX40L.

6. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the TNF ligand family member is 4-1BBL.

7. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the ectodomain of a TNF ligand family member comprises the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO: 3, SEQ ID NO:4, SEQ ID NO:99, SEQ ID NO: 100, SEQ ID NO: 101 and SEQ ID NO: 102.

8. The TNF family ligand trimer-containing antigen binding molecule of claim 1 ,

wherein said second heavy chain comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO: 103.

9. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the TNF ligand family member is OX40L.

10. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the ectodomain of a TNF ligand family member comprises the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:7.

11. The TNF family ligand trimer-containing antigen binding molecule of claim 1 ,

wherein said second heavy chain comprises the amino acid sequence of SEQ ID NO:8.

12. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof is fused at the C-terminal amino acid to a N-terminal amino acid of one of the subunits of the Fc domain.

13. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof is fused at the N-terminal amino acid to a C-terminal amino acid of one of the subunits of the Fc domain.

14. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the target cell antigen is selected from the group consisting of Fibroblast Activation Protein (FAP), Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), Carcinoembryonic Antigen (CEA), CD19, CD20, and CD33.

15. The TNF family ligand trimer-containing antigen binding molecule of claim 14 , wherein the target cell antigen is Fibroblast Activation Protein (FAP).

16. The TNF family ligand trimer-containing antigen binding molecule of claim 15 , wherein the moiety capable of specific binding to FAP comprises

(a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:10 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:11, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:12, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:13 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:14, or

(b) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 104, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:105 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:106, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:107, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:108 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:109.

17. The TNF family ligand trimer-containing antigen binding molecule of claim 15 , wherein the moiety capable of specific binding to FAP comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:16 and a variable light chain comprising the amino acid sequence of SEQ ID NO:17 or wherein the moiety capable of specific binding to FAP comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:110 and a variable light chain comprising the amino acid sequence of SEQ ID NO:111.

18. The TNF family ligand trimer-containing antigen binding molecule of claim 14 , wherein the target cell antigen is CEA.

19. The TNF family ligand trimer-containing antigen binding molecule of claim 18 , wherein the moiety capable of specific binding to CEA comprises a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:112, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:113 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:114, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:115, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:116 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:117.

20. The TNF family ligand trimer-containing antigen binding molecule of claim 18 , wherein the moiety capable of specific binding to CEA comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:118 and a variable light chain comprising the amino acid sequence of SEQ ID NO:119.

21. The TNF family ligand trimer-containing antigen binding molecule of claim 14 , wherein the target cell antigen is CD19.

22. The TNF family ligand trimer-containing antigen binding molecule of claim 21 , wherein the moiety capable of specific binding to CD19 comprises

(a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 120, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:121 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:122, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:123, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:124 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:125, or

(b) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 128, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:129 and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:130, and a VL domain comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:131, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:132 and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:133.

23. The TNF family ligand trimer-containing antigen binding molecule of claim 21 , wherein the moiety capable of specific binding to CD19 comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:126 and a variable light chain comprising the amino acid sequence of SEQ ID NO:127 or wherein the moiety capable of specific binding to CD19 comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:134 and a variable light chain comprising the amino acid sequence of SEQ ID NO:135.

24. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the Fc domain is an IgG1 Fc domain comprising the amino acid substitutions at positions 234 and 235 (EU numbering) and/or 329 (EU numbering).

25. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , comprising one moiety capable of specific binding to a target cell antigen.

26. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the antigen binding molecule comprises

(i) a first heavy chain comprising a VH domain comprising the amino acid sequence of SEQ ID NO:16 or a VH domain comprising the amino acid sequence of SEQ ID NO: 110,

(ii) a light chain comprising a VL domain comprising the amino acid sequence of SEQ ID NO: 17 or a VL domain comprising the amino acid sequence of SEQ ID NO:111, and

(iii) a second heavy chain comprising the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:103 or SEQ ID NO:8.

27. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the antigen binding molecule comprises

(i) a first heavy chain comprising a VH domain comprising the amino acid sequence of SEQ ID NO:118,

(ii) a light chain comprising a VL domain comprising the amino acid sequence of SEQ ID NO: 119, and

(iii) a second heavy chain comprising the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:103 or SEQ ID NO:8.

28. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , wherein the antigen binding molecule comprises

(i) a first heavy chain comprising a VH domain comprising the amino acid sequence of SEQ ID NO:126 or a VH domain comprising the amino acid sequence of SEQ ID NO: 134,

(ii) a light chain comprising a VL domain comprising the amino acid sequence of SEQ ID NO: 127 or a VL domain comprising the amino acid sequence of SEQ ID NO:135, and

(iii) a second heavy chain comprising the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:103 or SEQ ID NO:8.

29. The TNF family ligand trimer-containing antigen binding molecule of claim 1 , comprising two moieties capable of specific binding to a target cell antigen.

30. The TNF family ligand trimer-containing antigen binding molecule of claim 29 , wherein the antigen binding molecule comprises

(i) a first heavy chain comprising a VH domain of a Fab molecule capable of specific binding to a target cell antigen,

(ii) two light chains comprising each the VL domain of a Fab molecule capable of specific binding to a target cell antigen, and

(iii) a second heavy chain comprising a VH domain of a Fab molecule capable of specific binding to a target cell antigen and the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:103 or SEQ ID NO:8.

31. The TNF family ligand trimer-containing antigen binding molecule of claim 30 , wherein the antigen binding molecule comprises

(i) a first heavy chain comprising a VH domain comprising the amino acid sequence of SEQ ID NO:16 or a VH domain comprising the amino acid sequence of SEQ ID NO: 110,

(ii) two light chains comprising each a VL domain comprising the amino acid sequence of SEQ ID NO:17 or a VL domain comprising the amino acid sequence of SEQ ID NO: 111, and

(iii) a second heavy chain comprising a VH domain comprising the amino acid sequence of SEQ ID NO:16 or a VH domain comprising the amino acid sequence of SEQ ID NO: 110 and the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:103 or SEQ ID NO: 8.

32. The TNF family ligand trimer-containing antigen binding molecule of claim 30 , wherein the antigen binding molecule comprises

(i) a first heavy chain comprising a VH domain comprising the amino acid sequence of SEQ ID NO:118,

(ii) two light chains comprising each a VL domain comprising the amino acid sequence of SEQ ID NO:119, and

(iii) a second heavy chain comprising a VH domain comprising the amino acid sequence of SEQ ID NO:118 and the amino acid sequence of SEQ ID NO:5 or SEQ ID NO: 103 or SEQ ID NO:8.

33. The TNF family ligand trimer-containing antigen binding molecule of claim 30 , wherein the antigen binding molecule comprises

(i) a first heavy chain comprising a VH domain comprising the amino acid sequence of SEQ ID NO:126 or a VH domain comprising the amino acid sequence of SEQ ID NO: 134,

(ii) two light chains comprising a VL domain comprising the amino acid sequence of SEQ ID NO:127 or a VL domain comprising the amino acid sequence of SEQ ID NO: 135, and

(iii) a second heavy chain comprising a VH domain comprising the amino acid sequence of SEQ ID NO:126 or a VH domain comprising the amino acid sequence of SEQ ID NO:134 and the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:103 or SEQ ID NO:8.

34. The TNF family ligand trimer-containing antigen binding molecule of claim 7 , wherein the ectodomain of a TNF ligand family member comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:99.

35. An isolated polynucleotide encoding the TNF family ligand trimer-containing antigen binding molecule of claim 1 .

36. A vector comprising the isolated polynucleotide of claim 35 .

37. The vector of claim 36 wherein said vector is an expression vector.

38. A host cell comprising the vector of claim 36 .

39. A method for producing a TNF family ligand trimer-containing antigen binding molecule, comprising the steps of

(i) culturing the host cell of claim 38 under conditions suitable for expression of the antigen binding molecule, and

(ii) recovering the antigen binding molecule.

40. A pharmaceutical composition comprising the TNF family ligand trimer-containing antigen binding molecule of claim 1 and at least one pharmaceutically acceptable excipient.

Priority Claims (1)
EP 15161880 · Mar 31, 2015 · regional
Continuity (3)
Division 16653652 · Oct 15, 2019
Division 15087405 · Mar 31, 2016
Related Publication 20220267395A1 · Aug 25, 2022
References Cited (181)
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5821333A · Carter et al. · 1998 [cited by applicant]
US 6737056B1 · Presta et al. · 2004 [cited by applicant]
US 8552024B2 · Ackermann et al. · 2013 [cited by applicant]
US 8945571B2 · Hosse et al. · 2015 [cited by applicant]
US 8969526B2 · Baehner et al. · 2015 [cited by applicant]
US 9011847B2 · Bacac et al. · 2015 [cited by applicant]
US 9266938B2 · Ast et al. · 2016 [cited by applicant]
US 9346872B2 · Duerner et al. · 2016 [cited by applicant]
US 9481730B2 · Bruenker et al. · 2016 [cited by applicant]
US 10253110B2 · Bacac et al. · 2019 [cited by applicant]
US 10392445B2 · Amann et al. · 2019 [cited by applicant]
US 10464981B2 · Amann et al. · 2019 [cited by applicant]
US 10526413B2 · Amann et al. · 2020 [cited by applicant]
US 10577429B2 · Bacac et al. · 2020 [cited by applicant]
US 11149083B2 · Amann et al. · 2021 [cited by applicant]
US 11242396B2 · Bruenker et al. · 2022 [cited by applicant]
US 11267903B2 · Amann et al. · 2022 [cited by applicant]
US 11286300B2 · Ferrara Koller et al. · 2022 [cited by applicant]
US 11306154B2 · Amann et al. · 2022 [cited by applicant]
US 20130164286A1 · Chou et al. · 2013 [cited by applicant]
US 20130287802A1 · Govindappa et al. · 2013 [cited by applicant]
US 20140044674A1 · Duerner et al. · 2014 [cited by applicant]
US 20140370019A1 · Bruenker et al. · 2014 [cited by applicant]
US 20150038682A1 · Tsurushita et al. · 2015 [cited by applicant]
US 20150218244A1 · Emrich et al. · 2015 [cited by applicant]
US 20150315296A1 · Schaefer et al. · 2015 [cited by applicant]
US 20160060356A1 · Bacac et al. · 2016 [cited by applicant]
US 20160060357A1 · Bacac et al. · 2016 [cited by applicant]
US 20160159917A1 · Bruenker et al. · 2016 [cited by applicant]
US 20160200833A1 · Amann et al. · 2016 [cited by applicant]
US 20160340399A1 · Amann et al. · 2016 [cited by applicant]
US 20160340413A1 · Duerner et al. · 2016 [cited by applicant]
US 20170114141A1 · Amann et al. · 2017 [cited by applicant]
US 20170129962A1 · Regula et al. · 2017 [cited by applicant]
US 20170174786A1 · Bacac et al. · 2017 [cited by applicant]
US 20170247467A1 · Amann et al. · 2017 [cited by applicant]
US 20180230215A1 · Hofer et al. · 2018 [cited by applicant]
US 20180282409A1 · Ferrara Koller et al. · 2018 [cited by applicant]
US 20180340030A1 · Bruenker et al. · 2018 [cited by applicant]
US 20190016771A1 · Amann et al. · 2019 [cited by applicant]
US 20190120682A1 · Ziegler et al. · 2019 [cited by applicant]
US 20190185566A1 · Koller et al. · 2019 [cited by applicant]
US 20190194291A1 · Bruenker et al. · 2019 [cited by applicant]
US 20190211113A1 · Amann et al. · 2019 [cited by applicant]
US 20190382507A1 · Amann et al. · 2019 [cited by applicant]
US 20200071411A1 · Amann et al. · 2020 [cited by applicant]
US 20200079873A1 · Bacac et al. · 2020 [cited by applicant]
US 20200190206A1 · Koller et al. · 2020 [cited by applicant]
US 20200231691A1 · Grau-Richards et al. · 2020 [cited by applicant]
US 20200247904A1 · Amann et al. · 2020 [cited by applicant]
US 20200270321A1 · Amann et al. · 2020 [cited by applicant]
US 20200277392A1 · Amann et al. · 2020 [cited by applicant]
US 20200317774A1 · Hofer et al. · 2020 [cited by applicant]
US 20200325225A1 · Bacac et al. · 2020 [cited by applicant]
US 20200325238A1 · Bacac et al. · 2020 [cited by applicant]
US 20200347115A1 · Duerr et al. · 2020 [cited by applicant]
US 20200392237A1 · Bacac et al. · 2020 [cited by applicant]
US 20210009656A1 · Bruenker et al. · 2021 [cited by applicant]
US 20210024610A1 · Koller et al. · 2021 [cited by applicant]
US 20210070882A1 · Bacac et al. · 2021 [cited by applicant]
US 20210095002A1 · Claus et al. · 2021 [cited by applicant]
US 20210163617A1 · Ferrara et al. · 2021 [cited by applicant]
US 20210188992A1 · Bruenker et al. · 2021 [cited by applicant]
US 20210253724A1 · Claus et al. · 2021 [cited by applicant]
US 20210292426A1 · Duerr et al. · 2021 [cited by applicant]
US 20210324108A1 · Amann et al. · 2021 [cited by applicant]
US 20220025046A1 · Amann et al. · 2022 [cited by applicant]
US 20220025069A1 · Claus et al. · 2022 [cited by applicant]
US 20220073646A1 · Amann et al. · 2022 [cited by applicant]
AU 2011265482A1 · 2012 [cited by applicant]
AU 2011265482A2 · 2012 [cited by applicant]
AU 2013263717B2 · 2013 [cited by applicant]
CN 1756768A · 2006 [cited by applicant]
CN 101899106A · 2010 [cited by applicant]
CN 101951955A · 2011 [cited by applicant]
CN 102573922A · 2012 [cited by applicant]
CN 103221428A · 2013 [cited by applicant]
CN 103476795A · 2013 [cited by applicant]
EP 1736482 · 2006 [cited by applicant]
WO 2004039841A2 · 2004 [cited by applicant]
WO 2004069876A2 · 2004 [cited by applicant]
WO 200469876A2 · 2004 [cited by applicant]
WO 06121810 · 2006 [cited by applicant]
WO 2007000675A2 · 2007 [cited by applicant]
WO 2007014744A2 · 2007 [cited by applicant]
WO 2008022152A2 · 2008 [cited by applicant]
WO 200900538A1 · 2008 [cited by applicant]
WO 2009040550A1 · 2009 [cited by applicant]
WO 2009060112A1 · 2009 [cited by applicant]
WO 2010010051A1 · 2010 [cited by applicant]
WO 2011020783A2 · 2011 [cited by applicant]
WO 2011109789A2 · 2011 [cited by applicant]
WO 2012020006 · 2012 [cited by applicant]
WO 2012032433A1 · 2012 [cited by applicant]
WO 2012130471A1 · 2012 [cited by applicant]
WO 2012130831A1 · 2012 [cited by applicant]
WO 2014100762A1 · 2014 [cited by applicant]
WO 2014161845A1 · 2014 [cited by applicant]
WO 2014180754A1 · 2014 [cited by applicant]
WO 2015183902A1 · 2015 [cited by applicant]
WO 2015184203A1 · 2015 [cited by applicant]
WO 2016075278A1 · 2016 [cited by applicant]
WO 2016156291A1 · 2016 [cited by applicant]
WO 2019086500A2 · 2019 [cited by applicant]
WO 2019175071A1 · 2019 [cited by applicant]
WO 2020007817A1 · 2020 [cited by applicant]
WO 2020208049A1 · 2020 [cited by applicant]
WO 2020260329A1 · 2020 [cited by applicant]
WO 2021140130A1 · 2021 [cited by applicant]
WO 2021198335A1 · 2021 [cited by applicant]
Aggarwal, B.,, “Signalling pathways of the TNF superfamily: a double-edged sword” Nat Rev Immunol 3(9):745-756 (Sep. 1, 2003). [cited by applicant]
Ascierto, P. et al., “Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies” Semin Oncol 27(5):508-516 (Oct. 1, 2010). [cited by applicant]
Banner et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation” Cell 73:431-445 ( 1993). [cited by applicant]
Bauer, S., et al., “Targeted Bioactivity of Membrane-Anchored TNF by an Antibody-Derived TNF Fusion Protein” J Immunol 172(6):3930-3939 (Mar 15, 2004). [cited by applicant]
Baumann, R., et al., “Functional expression of CD134 by neutrophils” Eur J Immunol 34(8):2268-2275 (Aug. 1, 2004). [cited by applicant]
Bodmer et al., “The molecular architecture of the TNF superfamily” Trends Biochem Sci 27:19-26 ( 2002). [cited by applicant]
Bremer, E., et al., “Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy” ISRN Oncol 2013:1-25 (May 11, 2013). [cited by applicant]
Broll, K., et al., “CD137 Expression in Tumor Vessel Walls High Correlation With Malignant Tumors” Am J Clin Pathol 115(4):543-549 (Apr. 1, 2001). [cited by applicant]
Buechele, C., et al., “4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia” Eur J Immunol 42(3):737-748 (Mar. 1, 2012). [cited by applicant]
Carter, P., et al., “Bispecific human IgG by design” J Immunol Methods 248(1-2):7-15 (Feb. 1, 2001). [cited by applicant]
Choi, B., et al., “4-1BB Functions as a Survival Factor in Dendritic Cells” J Immunol 182(7):4107-4115 (Apr. 1, 2009). [cited by applicant]
Croft, M. et al., “The significance of OX40 and OX40L to T-cell biology and immune disease” Immunol Rev 229(1):173-191 (May 1, 2009). [cited by applicant]
Cuadros, C., et al., “Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic … [cited by applicant]
Curran, M., et al., “Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production” PLOS One 6(4):e19499, 1-11 (Apr. 29, 2011). [cited by applicant]
D. Müller et al., Journal of Immunotherapy 31(8):714-722 (Oct. 1, 2008). [cited by applicant]
Diehl, L., et al., “In Vivo Triggering Through 4-1BB Enables Th-Independent Priming of CTL in the Presence of an Intact CD28 Costimulatory Pathway” J Immunol 168(8):3755-3762 (Apr. 15, 2002). [cited by applicant]
Dubrot, J., et al., “Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ” Cancer Immunol Immun 59(8):1223-1233 (Aug. 1, 2010). [cited by applicant]
E. Bremer, ISRN Onconlogy 176(2):1-26 (Jan. 1, 2013). [cited by applicant]
Futagawa, T., et al., “Expression and function of 4-1 BB and 4-1BB ligand on murine dendritic cells” Int Immunol 14(3):275-286 (Mar. 1, 2002). [cited by applicant]
Gaugitsch et al., “A novel transiently expressed, integral membrane protein linked to cell activation. Molecular cloning via the rapid degradation signal AUUUA” J Biol Chem. 267(16):11267-11273 (Jun. 5, 1992). [cited by applicant]
Graff, C.P., et al., “Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C” Protein Eng Des Sel 17(4):293-304 (Apr. 28, 2004). [cited by applicant]
Guo, Z., et al., “Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.” J Transl Med 11(215):1-11 (Sep. 17, 2013). [cited by applicant]
Heinisch, I., et al., “CD137 activation abrogates granulocytemacrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils” Eur J Immunol 30(12):3441-3446 (Dec. 1, 2000). [cited by applicant]
Hornig, N., et al., “Combination of a Bispecific Antibody and Costimulatory Antibody-Ligand Fusion Proteins for Targeted Cancer Immunotherapy” J Immunother 35(5):418-429 (Jun. 1, 2012). [cited by applicant]
Hornig, N., et al., “Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy” Cancer Immunol Immunother 62(8):1369-1380 (May 17, 2013). [cited by applicant]
Ju, S., et al., “Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice.” Int J Cancer 122(12):2784-2790 (Jun. 15, 2008). [cited by applicant]
Kermer, V., et al., “Combining Antibody-Directed Presentation of IL-15 and 4-1BBL in a Trifunctional Fusion Protein for Cancer Immunotherapy” Mol Cancer Ther 13(1):112-121 (Jan. 1, 2014). [cited by applicant]
Kienzle, G., et al., “CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes” Int Immunol 12(1):73-82 (Jan. 1, 2000). [cited by applicant]
Kim, D., et al., “4-1BB Engagement Costimulates NKT Cell Activation and Exacerbates NKT Cell Ligand-Induced Airway Hyperresponsiveness and Inflammation” J Immunol 180(4):2062-2068 (Feb. 1, 2008). [cited by applicant]
Kim, Y. H., et al., “Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy.” Mol Cancer Ther 8(2):469-478 (Feb. 1, 2009). [cited by applicant]
Kwon, B., et al., “cDNA sequences of two inducible T-cell genes” PNAS USA 86(6):1963-1967 (Mar. 1, 1989). [cited by applicant]
Lee, H., et al., “Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody costimulatory signal” J Surg Res 169(1):e43-50 (Jul. 1, 2011). [cited by applicant]
Levitsky, V., et al., “The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time.” J Immunol 161(2):594-601 (Jun. 30, 1998). [cited by applicant]
Li and Ravetch, “Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies” Science 333(6045):1030-1034 (Aug. 19, 2011). [cited by applicant]
Lin, W., et al., “Fc-dependent expression of CD137 on human NK cells: insights into agonistic effects of anti-CD137 monoclonal antibodies” Blood 112(3):699-707 (Aug. 1, 2008). [cited by applicant]
Melero, I. et al., “Monoclonal Antibodies Against the 4-1BB T-cell Activation Molecule Eradicate Established Tumors” Nat Med 3(6):682-685 (Jun. 1, 1997). [cited by applicant]
Melero, I. et al., “NK1.1 Cells Express 4-1BB (CDw137) Costimulatory Molecule and Are Required for Tumor Immunity Elicited by Anti-4-1BB Monoclonal Antibodies” Cell Immunol 190(2 Suppl CI981396):167-172 (Dec. 15, 1998). [cited by applicant]
Merchant et al., “An efficient route to human bispecific IgG” Nat Biotechnol 16(7):677-681 ( 1998). [cited by applicant]
Morales-Kastresana, A., et al., “Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb” J Immunother Cancer 1(3):1-6 (May 29, 2013). [cited by applicant]
Morris et al., “Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain” Molecular Immunology 44:3112-3121 ( 2007). [cited by applicant]
Mueller, D. et al., “A Novel Antibody-4-1BBL Fusion Protein for Targeted Costimulation in Cancer Immunotherapy” J Immunother 31(8):714-722 (Oct. 1, 2008). [cited by applicant]
Mueller, N., et al., “Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization” FEBS J. 275(9):2296-2304 (May 1, 2008). [cited by applicant]
Murillo, O., et al., “In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb” Eur J Immunol 39(9):2424-2436 (Sep. 1, 2009). [cited by applicant]
Narazaki, H., et al., “CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells” Blood 115(10):1941-1948 (Mar. 11, 2010). [cited by applicant]
Nishimoto, H., et al., “Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor” Blood 106(13):4241-4248 (Dec. 15, 2005). [cited by applicant]
Olofsson, P., et al., “CD137 Is Expressed in Human Atherosclerosis and Promotes Development of Plaque Inflammation in Hypercholesterolemic Mice” Circulation 117(10):1292-1301 (Mar. 11, 2008). [cited by applicant]
Palazon, A., et al., “Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes” Cancer Res 71(3):801-811 (Feb. 1, 2011). [cited by applicant]
Schwarz, H., et al., “ILA, the Human 4-1BB Homologue, Is Inducible in Lymphoid and Other Cell Lineages” Blood 85(4):1043-1052 (Feb. 15, 1995). [cited by applicant]
Shao, Z., et al., “Mini-Review: CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction” J Leukocyte Biol 89(1):21-29 (Jan. 1, 2011). [cited by applicant]
Shi, W., et al., “Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment.” Anticancer Res 26(5A):3445-3453 (Sep. 2006). [cited by applicant]
Simeone, E. et al., “Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1” J Immunotoxcity 9(3):241-247 (Jul. 1, 2012). [cited by applicant]
Snell, L., et al., “T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy” Immunol Rev 244(1):197-217 (Nov. 1, 2011). [cited by applicant]
Stagg, J., et al., “Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy” PNAS 108(17):7142-7147 (Apr. 26, 2011). [cited by applicant]
Teng, M., et al., “CD1d-Based Combination Therapy Eradicates Established Tumors in Mice” J Immunol 183(3):1911-1920 (Aug. 1, 2009). [cited by applicant]
Von Kempis, J., et al., “Differentiation-dependent and stimulus-specific expression of ILA, the human 4-1BB-homologue, in cells of mesenchymal origin” Steoarthr Cartilage 5(6):394-406 (Nov. 1, 1997). [cited by applicant]
Wei, H., et al., “Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin” PLOS One 8(12):e84927, 1-11 (Dec. 19, 2013). [cited by applicant]
Wilcox, R., et al., “Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells” J Immunol 168(9):4262-4267 (May 1, 2002). [cited by applicant]
Wilcox, R., et al., “Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo” Blood 103(1):177-184 (Jan. 1, 2004). [cited by applicant]
Won, E., et al., “The Structure of the Trimer of Human 4-1BB Ligand Is Unique among Members of the Tumor Necrosis Factor Superfamily” J Biol Chem 285(12):9202-9210 (Mar. 19, 2010). [cited by applicant]
Written Opinion for PCT/2016/056765 ( Jun. 2, 2016). [cited by applicant]
Written Opinion of the International Searching Authority PCT/EP2015/076528 (Date of Mailing Mar. 2016). [cited by applicant]
Wyzgol, A., et al., “Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligan… [cited by applicant]
Zhang, N. et al., “Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors.” Clin Cancer Res 13(9):2758-2767 (May 1, 2007). [cited by applicant]
Zhang, X., et al., “CD137 Promotes Proliferation and Survival of Human B Cells” J Immunol 184(2):787-795 (Jan. 15, 2010). [cited by applicant]
Morales-Kastresana et al., “Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model” Clincial Cancer Research 19(22):6151-6162 ( 2013). [cited by applicant]
Song et al., “Activation of NF-κB1 by OX40 Contributes to Antigendriven T Cell Expansion and Survival” National Institute of Health/J Immunol 180(11):7240-7248 (2008). [cited by applicant]
Van Muijen et al., “Establishment and Characterization of a Human Melanoma Cell Line (MV3) Which is Highly Metastatic in Nude Mice” Int J Cancer 48:85-91 ( 1991). [cited by applicant]
Wattts, “TNF/TNFR Familymembers in Costimulation of T Cell Responses” Annu. Rev. Immunol 23:23-68 ( 2005). [cited by applicant]
Weinberg et al., “The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement” Journal of Leukocyte Biology 75:962-972 ( 2004). [cited by applicant]
Jiang and Huang, “Advances in the Study of the Role of CD137/CD137L in Antiviral Immunity” Chinese Journal of Cellular and Molecular Immunology 27(10):1161-1163 (2011). [cited by applicant]